✦ LIBER ✦

Interferon alpha 2b as Medical Selection for Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma: A Consecutive Study

✍ Scribed by Axel Bex; Martÿn Kerst; Henk Mallo; Wim Meinhardt; Simon Horenblas; Gÿsbert C. de Gast

Book ID: 113609062
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 109 KB
Volume: 49
Category: Article
ISSN: 0302-2838
DOI: 10.1016/j.eururo.2005.09.011

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The role of initial immunotherapy as sel

The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary in situ

✍ Axel Bex; Simon Horenblas; Wim Meinhardt; Natascha Verra; Bert de Gast 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 202 KB

The Role of Initial Immunotherapy as Sel

The Role of Initial Immunotherapy as Selection for Nephrectomy in Patients with Metastatic Renal Cell Carcinoma and the Primary Tumor in Situ

✍ A Bex; S Horenblas; W Meinhardt; N Verra; G.C de Gast 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 112 KB

A phase-II study of pegylated interferon

A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor

✍ Axel Bex; Henk Mallo; Martijn Kerst; John Haanen; Simon Horenblas; Gijsbert C. d 📂 Article 📅 2004 🏛 Springer-Verlag 🌐 English ⚖ 207 KB

290 A phase 2 study of pegylated interfe

290 A phase 2 study of pegylated interferon alfa-2B (peg-intron) for patients with metastatic renal cell carcinoma after removal of the primary tumour

✍ A. Bex; M. Kerst; H. Mallo; S. Horenblas; G. De Gast 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 220 KB

Interferon-α-2a with or without 13-cis r

Interferon-α-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma : Results of a randomized Phase II study (European Organization for Research and Treatment of Cancer Study 30951)

✍ Sophie D. Fosså; Gerald H. J. Mickisch; Pieter H. M. De Mulder; Simon Horenblas; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

## Background: In patients with metastatic renal cell carcinoma (mrcc), interferon-alpha (ifn) monotherapy leads to response rates of 5-15%, dependent on the selection of patients. in 1995, preclinical and clinical data indicated an improvement of these results if ifn was combined with 13-cis retin